108 related articles for article (PubMed ID: 35020560)
1. CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients' Survival.
Xu J; Wei L; Liu H; Lei Y; Zhu Y; Liang C; Sun G
Cancer Invest; 2022 Mar; 40(3):228-233. PubMed ID: 35020560
[TBL] [Abstract][Full Text] [Related]
2.
Klümper N; Wüst L; Saal J; Ralser DJ; Zarbl R; Jarczyk J; Breyer J; Sikic D; Wullich B; Bolenz C; Roghmann F; Hölzel M; Ritter M; Strieth S; Hartmann A; Erben P; Wirtz RM; Landsberg J; Dietrich D; Eckstein M
Oncoimmunology; 2023; 12(1):2267744. PubMed ID: 37868689
[TBL] [Abstract][Full Text] [Related]
3. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
4. Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Bayani J; Bartlett J; Xu B; Downes MR
J Clin Pathol; 2021 Jan; 74(1):53-57. PubMed ID: 32471889
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.
Micevic G; Thakral D; McGeary M; Bosenberg MW
Pigment Cell Melanoma Res; 2019 May; 32(3):435-440. PubMed ID: 30343532
[TBL] [Abstract][Full Text] [Related]
6. PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.
Kawahara T; Ishiguro Y; Ohtake S; Kato I; Ito Y; Ito H; Makiyama K; Kondo K; Miyoshi Y; Yumura Y; Hayashi N; Hasumi H; Osaka K; Muraoka K; Izumi K; Teranishi JI; Uemura H; Yao M; Nakaigawa N
BMC Urol; 2018 Nov; 18(1):97. PubMed ID: 30400941
[TBL] [Abstract][Full Text] [Related]
7. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
9. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of PD-L1 in bladder cancer.
Huang Y; Zhang SD; McCrudden C; Chan KW; Lin Y; Kwok HF
Oncol Rep; 2015 Jun; 33(6):3075-84. PubMed ID: 25963805
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
[TBL] [Abstract][Full Text] [Related]
13.
Goltz D; Gevensleben H; Dietrich J; Dietrich D
Oncoimmunology; 2017; 6(1):e1257454. PubMed ID: 28197377
[TBL] [Abstract][Full Text] [Related]
14. Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.
Ralser DJ; Klümper N; Gevensleben H; Zarbl R; Kaiser C; Landsberg J; Hölzel M; Strieth S; Faridi A; Abramian A; Dietrich D
J Immunother; 2021 Oct; 44(8):319-324. PubMed ID: 34347720
[TBL] [Abstract][Full Text] [Related]
15. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
17. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
19. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
20. The Expression Level of
Masuda T; Noda M; Kitagawa A; Hu Q; Fujii A; Ito S; Kosai K; Ando Y; Matsumoto Y; Ohtsu H; Uchida H; Ohno S; Mimori K
Anticancer Res; 2020 Jul; 40(7):3733-3742. PubMed ID: 32620612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
